brivaracetam: Clinical Trials

26 trials of brivaracetam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 3 terminated, 2 active not recruiting. 26 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 326Completed 21, Terminated 3, Active not recruiting 2

Follow brivaracetam: new trials by email Literature Review of brivaracetam trials Research Report on brivaracetam

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 3Active not recruitingUCB Biopharma SRL702024-07-102026-08-27
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
brivaracetam, Placebo - Spinal Cord Injuries, Neuropathic Pain
Phase 3CompletedUniversity of Minnesota442023-01-012026-03-18
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 3CompletedUCB Biopharma SRL842022-03-302025-10-22
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam, Placebo - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 3CompletedUCB Biopharma SRL1542021-07-292026-10-30
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Brivaracetam - Epilepsy
Phase 3Active not recruitingUCB Biopharma SRL842021-03-112026-11-17
Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy
Brivaracetam - Epilepsy, Focal
Phase 3CompletedJiangxi Qingfeng Pharmaceutical Co. Ltd.1412021-02-072026-05-04
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
Brivaracetam (BRV) intravenous (iv), Brivaracetam (BRV) oral - Electroencephalographic Neonatal Seizures
Phase 3TerminatedUCB Biopharma SRL92019-05-072024-04-08
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy
Phase 3CompletedUCB Biopharma S.P.R.L.102019-01-042021-04-13
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Placebo, Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy
Phase 3CompletedUCB Biopharma SRL4492017-08-222025-10-14
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy
Phase 3CompletedUCB Biopharma SRL2072017-08-052025-07-29
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
Brivaracetam - Epilepsy
Phase 3CompletedUCB Pharma SA262012-10-012018-07-11
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
Brivaracetam - Epilepsy
Phase 3CompletedUCB Pharma SA292012-07-012018-07-11
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
Brivaracetam (BRV) - Epilepsy
Phase 3CompletedUCB Pharma SA2572011-08-012025-10-20
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion - Epilepsy
Phase 3CompletedUCB Pharma1052011-08-012018-07-11
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
Brivaracetam - Epilepsy
Phase 3CompletedUCB BIOSCIENCES, Inc.7672011-05-112021-08-17
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country - Epilepsy
Phase 3CompletedUCB Pharma7682010-12-012022-07-22
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
Brivaracetam - Epilepsy
Phase 3CompletedUCB Pharma1082008-11-012018-07-11
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Brivaracetam - Epilepsy
Phase 3TerminatedUCB Pharma882008-08-012018-07-11
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Brivaracetam - Epilepsy
Phase 3TerminatedUCB Pharma622008-08-012018-07-11
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
Placebo, Brivaracetam - Epilepsy
Phase 3CompletedUCB Pharma SA4802007-10-012018-04-03

Showing 20 of 26. Sign in to see all of them.

Conditions studied

Epilepsy (21)  ·  Epilepsy, Absence (3)  ·  Myoclonic Epilepsies, Progressive (2)  ·  Myoclonus (2)  ·  Unverricht-Lundborg Syndrome (2)  ·  Epilepsies, Partial (1)  ·  Neuralgia (1)  ·  Spinal Cord Injuries (1)

Sponsors

UCB Pharma (8)  ·  UCB Biopharma SRL (7)  ·  UCB Pharma SA (6)  ·  Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1)  ·  UCB BIOSCIENCES, Inc. (1)  ·  UCB Biopharma S.P.R.L. (1)  ·  UCB PHARMA Inc. (US) (1)  ·  University of Minnesota (1)

Countries

United States (18)  ·  Italy (14)  ·  Germany (13)  ·  France (12)  ·  Spain (11)  ·  Belgium (9)  ·  Czechia (9)  ·  Canada (8)  ·  Hungary (8)  ·  Poland (7)  ·  Sweden (7)  ·  Finland (6)  ·  Japan (6)  ·  Mexico (6)  ·  United Kingdom (6)

Top investigators

Ricardo Battaglino, PhD (1)  ·  Zhen Hong, MD (1)

Results publications

PMID 26899665, PMID 34218211, PMID 33461041, PMID 35285519, PMID 27265725, PMID 27335114, PMID 27589414, PMID 27608437, PMID 27988967, PMID 28004320, PMID 28236727, PMID 28279891, PMID 29414542, PMID 29908435, PMID 32432339, PMID 34155568, PMID 35582748, PMID 38788664, PMID 26471380, PMID 26666500, PMID 29486396, PMID 33780735, PMID 36435010, PMID 24116853, PMID 24256083, PMID 24446953, PMID 26432008, PMID 32221987, PMID 35844134, PMID 37597326, PMID 38049197, PMID 40549270, PMID 40737960, PMID 40944847

NIH funding

2008 (4), 2023 (2), 2004 (1), 2015 (1)